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Abstract: (1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume
(PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers
for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different
software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods:
68Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving
chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were
calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji
Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and
quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV,
TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA
(∆PSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing
absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical
comparability of both software algorithms. For clinical agreement, classifying therapy response did
not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive
correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in
our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA
determined by Syngo.via and FIJI appears feasible.
Keywords: prostate-specific membrane antigen (PSMA); metabolic tumour volume (MTV); total
lesion PSMA; biomarker; software; comparability; agreement
1. Introduction
Imaging-derived biomarkers and clinical response classification systems such as RECIST 1.1 [1]
for CT scans and PERCIST 1.0 for PET/CT scans [2] play a crucial role in cancer care. Among potential
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biomarkers, metabolic tumour volume seems to be especially promising for clinicians as it represents a
measure for the whole-body tumour burden. This principal attractiveness has led to several studies
examining metabolic tumour volume and total lesion values for various solid and haematological
malignancies, e.g., 18F-FDG PET/CT scans and their prognostic impact for tumour entities such as
cervical cancer [3], head and neck [4,5], pancreatic cancer [6], Hodgkin’s lymphoma [7], ovarian [8]
and prostate cancer (PCa) [9].
Given the essential role of PSMA PET/CT-based diagnostics in modern PCa care, the potential
predictive value of whole-body PSMA tumour volume (PSMA-TV) and whole-body total lesion PSMA
(TL-PSMA) derived from PSMA PET/CT scans has been examined [10].
However, a variety of software algorithms delivers metabolic tumour volume markers such as
PSMA-TV and TL-PSMA. Accordingly, studies examining metabolic tumour volume derived from
PSMA PET/CT used different software tools [11–14].
For researchers, it is currently unclear whether results obtained by different programs are
comparable between different centres, e.g., in large multicentre studies. Likewise, comparability of
data on tumour volume is critical when patients change the diagnostic department and are rated with a
different software tool. In general, for prospective biomarkers in clinical use, it should be clear whether
choice of the calculation tool influences results. To our knowledge, there are no existing data on these
topics for PSMA-TV and TL-PSMA.
For this reason, we calculated PSMA-TV and TL-PSMA with Syngo.via and the Beth Israel plugin
for FIJI (Fiji Is Just ImageJ, open source project) from PSMA PET/CTs of castration resistant prostate
cancer (CRPC) patients, representing a cohort of late stage disease patients with a high tumour burden.
Moreover, we assessed dynamics induced by chemotherapy (docetaxel or cabazitaxel) by determining
PSMA-TV and TL-PSMA with both algorithms at two time points – before and after completion or
termination of chemotherapy. We analyzed statistical comparability of both software tools using
Bland–Altmann plotting. Clinical agreement was estimated by matching PSMA-TV, TL-PSMA and
relative changes of both variables during chemotherapy with changes in serum PSA levels (∆PSA) and
PERCIST (Positron Emission Response Criteria in Solid Tumors).
2. Materials and Methods
2.1. Study Cohort
We searched our database of n = 1025 patients who received a PSMA PET/CT between July
2014 and December 2018 at our centre and identified a clinically distinct subgroup of n = 21 patients
receiving docetaxel or cabazitaxel as systemic chemotherapy for metastatic PCa in a castration-resistant
stage (CRPC). All patients included had at least one 68Ga-PSMA PET/CT in a three months period
before chemotherapy (in the following named baseline) and another scan in a four months period after
completion or termination of chemotherapy (follow-up). Serum prostate-specific antigen (PSA) levels
were determined at baseline and after completion or termination of chemotherapy. Table 1 further
outlines the characteristics of our study cohort.
All findings, data acquisition and processing in this study comply with the ethical standards
laid down in the latest Declaration of Helsinki as well as with the statutes of the Ethics Committee
of the University of Würzburg concerning anonymized retrospective medical studies. There were
no fundamental ethical and legal objections to the evaluation of the listed data (# 20,191,106 02 from
November 2019).
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Table 1. Study cohort of n = 21 patients receiving chemotherapy for castration-resistant prostate cancer
(CRPC). PSMA: prostate-specific membrane antigen; PSA: prostate-specific antigen.
Clinical Characteristics n = 21
age [years]
median (range) 72 (55–93)
previous therapies [n]
radical prostatectomy 11 (52%)
radiotherapy 13 (62%)
androgen deprivation therapy 21 (100%)
brachytherapy 1 (5%)
Abiraterone 10 (48%)
Alpharadin 2 (10%)
177Lu-PSMA 2 (10%)
Chemotherapy
docetaxel [n] 15 (71%)
cycles; median (range) 6 (3–13)
<6 cycles [n] 7 (32%)
cabazitaxel [n] 7 (32%)
cycles; median (range) 4 (2–8)
serum PSA baseline [ng/mL]
median (range) 15.0 (0–800)
Gleason score
median (range) 8 (6–10)
metastases localization [n]
bone 16 (76%)
lymph nodes 18 (86%)
liver 4 (19%)
lungs 2 (10%)
local recurrence [n] 4 (19%)
time between baseline PET/CT and PSA [d]
median (range) 13 (1–59)
time between follow-up PET/CT and PSA [d]
median (range) 12 (0–52)
time between end of chemotherapy and PET/CT [d]
median (range) 37 (11–120)
2.2. PSMA PET/CT Imaging Protocol
Images were obtained with 68Ga-PSMA I&T (68Ga-PSMA) which was prepared using a cassette-based
radiotracer synthesis module (Scintomics, Fürstenfeldbruck, Germany). Briefly, the eluate (68Ga3+ in 0.1 M
HCl) of a 68Ge/68Ga-generator (GalliaPharm, Eckert & Ziegler AG, Berlin, Germany) was transferred to a
cation exchange cartridge, eluted, added to a solution of 20 µg PSMA I&T (Scintomics, Fürstenfeldbruck,
Germany) in HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)-buffer and heated. The product
was immobilized on a SepPak C18-cartridge, washed with water und eluted with ethanol/water. The final
eluate was passed through a sterile filter into a sterile vial und diluted with phosphate buffer solution.
Variations in injected radiotracer activity were caused by the short half-life of 68Ga and variable elution
efficiencies obtained during the lifetime of the 68Ge/68Ga radionuclide generator.
All patients received a diluted oral contrast agent (Peritrast CT 400 mg iodine/mL). Furosemide
10mg was administered at the time point of tracer injection. Patients underwent 68Ga-PSMA PET/CT
from the skull base to the mid-thigh using a Biograph mCT scanner (Siemens Medical Solutions,
Erlangen, Germany) after an average incubation time of 71 min (interquartile range (IQR) 54–82 min;
baseline)/82 min (IQR 64–84 min; follow-up). A mean of 119 MBq 68Ga-PSMA (IQR 108–132 MBq;
baseline)/125 MBq (IQR 105–144 MBq; follow-up) was injected per patient. PET/CT included a
diagnostic CT scan (mA modulated, 120kV, 5 mm slice thickness) in the portal venous phase (70 s after
injection of Imeron 350 at 1 mL/kg body weight). All PET scans were acquired in three-dimensional
mode with an acquisition time of 2 min per bed position. Images were reconstructed iteratively
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using an ordered subset expectation maximization algorithm (3 iterations, 24 subsets) followed by
a post-reconstruction Gaussian filter smoothing (2 mm full-width at half-maximum; Siemens TrueX,
Siemens Healthineers, Erlangen, Germany).
2.3. Image Analysis
First, PET/CT images were analysed using a dedicated workstation equipped with a commercial
software package (Syngo.via; VB30A, Siemens Healthcare, Erlangen, Germany). For comparison of
the derived parameters, we then used the Beth Israel plugin for FIJI [15], a freely available shareware
from the Beth Israel Deaconess Medical Center (Boston, MA, USA), Division of Nuclear Medicine and
Molecular Imaging.
All lesions with visually higher uptake compared to environment were rated as PSMA-positive,
suggesting local recurrence or metastases. Structures with known non-malignant uptake of PSMA
(e.g., salivary glands and coeliac ganglia) were excluded. Diagnostic decisions were made by consensus
of two experienced nuclear medicine physicians (A.K.B., C.L.) and one radiologist. For all suspected
pathological lesions, mean and maximum standardized uptake value (SUVmean, SUVmax) and the
metabolic tumour volume were determined with two different software applications (Syngo.via and
the Beth Israel plugin for FIJI—in the following named FIJI). In addition, we determined the hottest
lesion (highest SUVmax of all lesions) for each patient.
In both software applications, we used a semi-automatic analysis (Syngo.via with volumes of
interest (VOIs) with isocontours; FIJI with the automatic segmentation function as described by the
developers). For both applications, the threshold was set by a 3 cm spherical region of interest (ROI) in
the liver adapted from PERCIST and PROMISE criteria (threshold: 1.5 × liver mean + 2 × standard
deviation) [2,16]. In case of liver metastases, we set a threshold based on a 1 cm diameter ROI in
descending thoracic aorta extended over 2 cm z-axis (threshold: 2 × aortic mean + 2 × standard
deviation). After automated analysis, a lesion-based manual control was carried out by two researchers
(P.E.H., M.H.). Decisions were made by consensus. From these parameters, the PSMA uptake of each
lesion was calculated by multiplying the respective metabolic tumour volume with SUVmean [10].
Summing up all lesions revealed PSMA-TV and TL-PSMA for each patient.
2.4. Clinical Response Criteria
We calculated changes in serum PSA levels in order to determine biochemical response (BR). Partial
response (PR), stable disease (SD) and progressive disease (PD) were used as defined previously [17].
As summarized in Table 2, we applied the following clinical endpoint criteria. Relative changes in
serum PSA levels, SUVmax (PERCIST criteria) as well as PSMA-TV and TL-PSMA were determined by
comparing values at the time point of follow-up and baseline (rel. ∆X [%] = Xfollow-up/Xbaseline × 100).
We arbitrarily set a relative decrease or a relative increase of 30% as threshold for PR and PD (see
Table 2).
To assess PET/CT-derived response, we used the PERCIST 1.0 criteria and adapted them to PSMA
PET/CT [2]. The lesion with the highest SUVmax was determined for both PET/CT studies regardless
of the overall number of lesions.
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Table 2. Biochemical and PET/CT-derived clinical response criteria applied within our study.
BR: biochemical response; PSA: prostate-specific antigen; PSMA: prostate-specific membrane
antigen; SUVmax: maximum standardized uptake value. PSA, SUVmax, PSMA-derived tumour
volume (PSMA-TV) and total lesion-PSMA (TL-PSMA) represent follow up values as percentage of
baseline values.
Complete Response
CR
Partial Response
PR
Stable Disease
SD
Progressive Disease
PD
BR PSA negative PSA ≤ 50% 50% < PSA < 125% PSA ≥ 125%
PERCIST no malignant PSMA
uptake
SUVmax ≤ 70% 70% < SUVmax < 130% SUVmax ≥ 130% or
new PSMA-lesion
PSMA-TV no measurable PSMA-TV PSMA-TV ≤ 70% 70% < PSMA-TV < 130% PSMA-TV ≥ 130%
TL-PSMA no measurable TL-PSMA TL-PSMA ≤ 70% 70% < TL-PSMA < 130% TL-PSMA ≥ 130%
2.5. Statistical Analysis
We performed statistical analyses with SPSS software (Version 25, IBM Corp., Armonk, NY,
USA) and applied Shapiro-Wilk tests for normal distribution. Due to the non-normal distribution
of our datasets at baseline and follow-up, we used median and interquartile range (IQR) for further
characterization. We then tested for significant differences between non-normally distributed
datasets by applying Wilcoxon rank tests. For correlation analyses, we used the Spearman rank
correlation coefficient.
We performed a power analysis by applying the G*Power tool [18]. There were no existing
preliminary data regarding differences between software solutions. However, as implied by our
arbitrarily set clinical response criteria (±30% changes in PSMA-TV and TL-PSMA; see Section 2.4.),
we wanted to rule out that clinically relevant differences between the two software solutions were
missed within our study. Therefore, effect size of the difference was considered large and consecutively
set at 0.7. For a power of 80% and α = 0.05, the required sample size was n = 19.
Figures—including Bland-Altman plots—were generated with PRISM (Graphpad Software, San
Diego, CA, USA). In specific, Bland–Altman diagrams [19] were used for assessing the statistical
agreement between values derived from both software algorithms, Syngo.via and FIJI. Instead of
absolute differences, we examined relative differences between both algorithms within Bland–Altman
plotting. Dotted lines in the plots represented the limits of agreement of both applications for each
timepoint and each biomarker candidate—assuming a reasonable statistical comparability of both
software solutions within these boundaries. Repeatability coefficients (RC) were calculated from the
same dataset as described previously [20]: RC = 1.96 × standard deviation of relative differences.
3. Results
We identified n = 21 PCa patients from our single-centre 68Ga-PSMA PET/CT database undergoing
docetaxel or cabazitaxel chemotherapy as systemic treatment for CRPC. Each patient had at least one
baseline PET/CT scan and one follow-up scan after completion or termination of chemotherapy.
3.1. PSMA-TV and TL-PSMA during Chemotherapy—Determined by Syngo.via and FIJI
In a first step, we determined PSMA-TV and TL-PSMA for each patient from baseline and
follow-up PET/CT scans by applying both, the Syngo.via and the FIJI software. Figure 1 illustrates
respective results (raw data for each patient are available in Supplementary Table S1).
Regarding PSMA-TV at baseline (Figure 1a) and follow-up (Figure 1b), applying Syngo.via
revealed a median value of 41.7 cm3 (IQR: 124.3 cm3) at baseline and a median of 70.8 cm3 (IQR:
598.2 cm3) at follow-up. Applying the FIJI software yielded comparable PSMA-TV values for both
time points—resulting in a median of 39.3 cm3 (IQR: 125.4 cm3) for baseline (p = 0.48) and a median
of 75.1 cm3 (IQR: 485.4 cm3) for follow-up PET/CT scans (p = 0.43). Correspondingly, TL-PSMA
determined by FIJI was also comparable at baseline and follow-up (Figure 1c,d). While applying
Syngo.via yielded a median of 406.3 cm3 (IQR: 1794.4 cm3) and 663.39 cm3 (IQR: 3687.7 cm3) for
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baseline and follow-up scans, using FIJI led to a median of 411.6 cm3 (IQR: 1742.8 cm3) (p = 0.39) and
626.3 cm3 (IQR: 5196.7 cm3) (p = 0.71), respectively.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 7 of 14 
 
 
Figure 1. Statistical agreement of PSMA-TV and TL-PSMA determined by Syngo.via and FIJI at 
baseline and follow-up. (a,b) PSMA-TV for each patient at baseline (a) and follow-up (b)—determined 
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Figure 1. Statistical agreement of PSMA-TV and TL-PSMA determined by Syngo.via and FIJI at baseline
and follow-up. (a,b) PSMA-TV for each patient at baseline (a) and follo -up (b)—determined by
Syngo.via and FIJI. (c,d) TL-PSMA at baseline (c) and follow-up (d) determined by both software
algorithms. (e–h) Bland–Altman diagrams for illustration and assessment of statistical comparability
for each patient. Single outliers with a significant divergence between values determined by Syngo.via
and FIJI were marked in red—all others were depicted within a range of 1.96 × standard deviation (SD).
PSMA: prostate-specific membrane antigen; PSMA-TV: PSMA tumour volume; TL-PSMA: total lesion
PSMA; ns: not significant.
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To assess statistical agreement of Syngo.via- and FIJI-determined PSMA-TV and TL-PSMA,
we next plotted Bland-Altman diagrams for PSMA-TV and TL-PSMA at baseline and follow-up
(Figure 1e–h). In line with PSMA-TV and TL-PSMA values illustrated in Figure 1a–d, Bland–Altman
diagrams confirmed a good statistical comparability of both software algorithms—with 20 of 21
measurements being within the calculated limits of statistical agreement (1.96 × standard deviation of
relative differences; dotted lines in Figure 1e–h) at each time point. Only one data point within each
plot was located outside the boundaries of statistical agreement (indicated by the dotted lines)—with
relative differences of both software tools indicated on the y axis. These outliers (marked in red)
represented measurements of only two patients from our study cohort: patient #5 for baseline values
of PSMA-TV (Figure 1e) and TL-PSMA (Figure 1g) and patient #11 for follow-up values of PSMA-TV
(Figure 1f) and TL-PSMA (Figure 1h).
When calculating repeatability coefficients (RC), PSMA-TV at follow-up (Figure 1f) revealed the
lowest RC of 40.4%, followed by PSMA-TV at baseline with 42.4% (Figure 1e), TL-PSMA at follow-up
with 41.5% (Figure 1h) and TL-PSMA at baseline with 48.0% (Figure 1g).
3.2. PSMA-TV and TL-PSMA as Imaging-Derived Biomarkers in CRPC
To further assess the clinical agreement of metabolic tumour volume determined with different
software solutions, we calculated correlation of PSMA-TV and TL-PSMA with serum PSA levels.
Table 3 illustrates our results. We found highest correlation for follow-up data—with % = 0.86 reaching
its maximum for PSMA-TV determined by FIJI and serum PSA at time of follow-up. Regarding relative
changes, application of FIJI yielded comparable correlations for ∆PSMA-TV and ∆TL-PSMA with
∆PSA (% = 0.67 and % = 0.69, respectively) compared to Syngo.via (% = 0.70 and % = 0.67, respectively).
In summary, applying Syngo.via and FIJI delivered comparable and significantly positive correlation
coefficients for PSMA-TV/TL-PSMA and serum PSA.
Table 3. Spearman rank correlation coefficients of PSMA-TV/TL-PSMA values (baseline, follow-up,
relative change) and corresponding serum prostate-specific antigen (PSA) levels—according to the
software solution applied. PSMA: prostate-specific membrane antigen; PSMA-TV: PSMA tumour
volume; TL-PSMA: total lesion PSMA.
PSA Baseline PSA Follow-Up rel. ∆ PSA [%]
Syngo.via
PSMA-TV baseline 0.63 (p < 0.01)
PSMA-TV
follow-up 0.84 (p < 0.01)
∆PSMA-TV [%] 0.70 (p < 0.01)
TL-PSMA baseline 0.55 (p = 0.019)
TL-PSMA
follow-up 0.80 (p < 0.01)
∆TL-PSMA [%] 0.67 (p < 0.01)
FIJI
PSMA-TV baseline 0.64 (p < 0.01)
PSMA-TV
follow-up 0.86 (p < 0.01)
∆PSMA-TV [%] 0.67 (p < 0.01)
TL-PSMA baseline 0.56 (p = 0.016)
TL-PSMA
follow-up 0.84 (p < 0.01)
∆TL-PSMA [%] 0.69 (p < 0.01)
In a next step, we stratified all CRPC patients in CR, PR, SD and PD subgroups—depending on
∆PSMA-TV and ∆TL-PSMA. As already described in Table 2, we used an arbitrarily set threshold of
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±30% change. Table 4 shows patients’ classifications according to the Syngo.via and the FIJI software
as well as the established clinical endpoints PERCIST and BR.
Table 4. Clinical response in terms of PERCIST criteria, biochemical response (BR), ∆PSMA-TV and
∆TL-PSMA for castration-resistant prostate cancer (CRPC) patients calculated with the Syngo.via
and the FIJI software. Patients with 1 were rated PD in PERCIST due to new lesions. For patient
#14, changes in PSMA-TV and TL-PSMA were not calculated due to tracer extravasation at baseline
PET/CT—classification according to PERCIST was applicable due to a new lesion at follow-up. PR:
partial response; SD: stable disease; PD: progressive disease.
Patient PERCIST BR ∆PSMA-TV ∆TL-PSMA ∆PSMA-TV ∆TL-PSMA
Syngo.via Syngo.via FIJI FIJI
#1 SD SD PR PR PR PR
#2 PD 1 PD PD PD PD
#3 PR PR PR PR PR PR
#4 PD 1 PD PR PR PR PR
#5 PR PR PR PR PR PR
#6 PD 1 PD PD PD PD PD
#7 PR PR PR PR PR PR
#8 PD 1 PD SD SD SD SD
#9 PD SD SD SD SD SD
#10 PD SD PD PD PD PD
#11 PD PD PD PD PD PD
#12 PD 1 PD PD PD PD PD
#13 PD 1 PD PD PD PD PD
#14 PD 1 PD
#15 PD PR PD PD PD PD
#16 PD 1 PR PR PR PR PR
#17 PD 1 PR PR PR PR
#18 PR PD SD SD SD SD
#19 PD 1 PD PD PD PD PD
#20 PD PD PD PD PD PD
#21 PD 1 PD SD SD SD SD
Of note, stratifying patients according to ∆PSMA-TV and ∆TL-PSMA response criteria yielded
identical response classifications for each patient—independent of the software algorithm.
To learn more about the prognostic potential of ∆PSMA-TV and ∆TL-PSMA in our small study
cohort, we patient-wise compared our therapy response subgroups based on metabolic tumour volume
with the clinically established endpoints BR and PERCIST. Regarding BR, five patients showed a PR,
three patients were classified as SD and eleven patients as PD. Two patients (#2 and #17) had very low
PSA values, which had not reflected treatment responses in previous therapy lines. For this reason,
they were marked as PSA-negative PCa by responsible urologists. Accordingly, we did not perform
BR classification.
Response assessment based on PERCIST criteria showed four patients with PR, one patient with
SD and sixteen patients with PD. Ten patients were rated PD due to new lesions and not due to
rising SUVmax. Calculating ∆PSMA-TV and ∆TL-PSMA with Syngo.via, seven patients showed PR,
four patients SD and nine patients PD, respectively. Analyses based on the FIJI software yielded
seven patients with PR, four patients with SD and nine patients PD, regarding ∆PSMA-TV and
∆TL-PSMA, respectively.
In terms of agreement between ∆PSMA-TV, ∆TL-PSMA and BR, there were seven patients with a
disagreement—in six patients, the discrepancy appeared relevant (non-PD vs. PD classification). These
six patients are further characterised in Table 5.
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Table 5. Relative changes in PSA, ∆PSMA-TV (Syngo.via) and overall survival (OS) in six patients with
clinically relevant disagreement between PSMA-TV and BR (non-PD vs. PD classification). PR: partial
response; SD: stable disease; PD: progressive disease.
Patient BR ∆PSMA-TV ∆PSA [%] ∆PSMA-TV [%] OS [d] Death
#4 PD PR +238% −76% 216 Yes
#8 PD SD +786% −21% 235 Yes
#10 SD PD +9% +42% 1169 No
#15 PR PD −99% +213% 720 No
#18 PD SD +291% −14% 328 Yes
#21 PD SD +66% +26% 1556 No
Of note, a PD classification according to BR was associated with death during follow-up in three of
four patients (#4, #8, #18)—despite a reduction of PSMA-TV in all three cases. In contrast, both patients
classified PD solely based on ∆PSMA-TV (#10, #15) survived post-therapeutic follow-up period.
4. Discussion
PET/CT-derived response criteria are promising biomarkers for monitoring cancer therapies.
Among them, FDG PET/CT-derived PERCIST criteria were established first [2]. In the following,
researchers evaluated metabolic tumour volume (MTV) and total lesion glycolysis (TLG) from FDG
PET/CT scans for their prognostic potential in entities such as cervical or pancreatic cancer [3,6], thereby,
serving as an intuitive measure and a medium for quantifying the whole-body tumour burden.
Paying tribute to the growing importance of PSMA PET/CT imaging, PET/CT-derived criteria
were transferred accordingly to PCa patient subgroups. For 68Ga-PSMA PET/CT scans, adapted
PERCIST criteria performed better than morphological criteria such as RECIST in metastatic PCa [21],
177Lu-PSMA-therapy [22] or patients undergoing docetaxel therapy [17]. Schmuck et al. were the
first to analyse the overlap of PSMA-TV, TL-PSMA and BR for PCa patients [10]. However, there are
scarce data regarding metastatic PCa patients with a high tumour burden—especially patients on
taxane-based chemotherapy.
Going one step back, it is also unknown whether choosing different software solutions for
determining metabolic tumour volume influences outcome. For calculation of PSMA-TV and TL-PSMA,
different authors used different software (Syngo.via, METAVOL, LifeX or custom-made programs)
and currently it is unclear whether their results are seamlessly comparable [11–14]. To address these
issues, we analysed pre- and post-therapeutic 68Ga-PSMA PET/CT scans of PCa patients receiving
chemotherapy – first, with Syngo.via and afterwards with the FIJI algorithm.
4.1. Statistical Agreement of PSMA-TV and TL-PSMA Determined with Syngo.via and FIJI
After determining PSMA-TV and TL-PSMA with both software solutions, statistical analysis
revealed no significant differences between the aggregate amounts of PSMA-TV or TL-PSMA
determined by Syngo.via or FIJI—thereby indicating that there is no systematic bias or shift caused
by one of the software solutions. Next, we compared relative differences between Syngo.via and FIJI
for each patient at both time points and used Bland–Altman diagrams for illustration and further
calculation. In line with our previous findings, we found a strong statistical comparability for 20 of the
21 CRPC patients examined. In contrast to our results, Kanoun et al. presented divergent results when
comparing FDG PET/CTs examined with FIJI and another commercial software application. However,
these differences did not have a significant impact on the prognosis of Hodgkin’s lymphoma patients.
Moreover, relative changes did not differ significantly [23].
4.2. Clinical Agreement of PSMA-TV and TL-PSMA Determined with Syngo.via and FIJI
We then examined PSMA-TV and TL-PSMA determined by Syngo.via and FIJI as imaging-derived
biomarkers—starting with Spearman rank correlations with serum PSA levels at baseline and follow-up.
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We were able to show significant correlations between serum PSA values and PSMA-TV as well as
TL-PSMA at baseline and follow-up in accordance to previous studies [10,11,14,24]. These earlier
publications showed correlations between relative ∆PSMA-TV and ∆PSMA-TL with relative changes
in serum PSA-levels in patients undergoing androgen deprivation, radiotherapy and radioligand
therapy [10,12,24]. To our knowledge, our data are the first revealing significant correlations of
∆PSMA-TV, ∆TL-PSMA and ∆PSA for a cohort of patients undergoing taxane-based chemotherapy.
In a patient-wise approach, we compared ∆PSMA-TV and ∆TL-PSMA with the common clinical
endpoints BR and PERCIST. Therapy-induced changes in PSMA-TV and TL-PSMA were arbitrarily
classified as PR or PD, when a reduction of ≥30% or an increase of ≥30% occurred. Of note, classifying
patients’ therapy response according to∆PSMA-TV and∆TL-PSMA led to identical results independent
of the software applied.
In general, patient subgroups with contradictory results across clinical endpoints—such as BR,
PERCIST and PSMA-TV as well as TL-PSMA—surely merit further investigation. Specifically, some
patients were classified PD according to PERCIST criteria, while classification according to PSMA-TV
and TL-PSMA yielded a SD or PR rating. As described above, classification according to PERCIST was
derived from FDG PET/CT and is not yet established for PSMA PET/CT. While it is mainly based on
changes in SUVmax, any new lesion leads to a PD rating. In our cohort, there were ten patients with
SD or PR according to SUVmax values, but they were rated PD because of new lesions. Regarding
this definition, the apparent discrepancy between PERCIST and other PET parameters is put into
perspective. Further research on this topic is needed, as an in-depth analysis of the prognostic impact of
PERCIST on the overall survival is limited due to our small sample size and was not the primary scope
of our study. Brito et al. for example published an approach where they suggested using TL-PSMA for
separating PCa patients into two groups with a high or low tumour burden instead of only counting
the number of lesions [11].
Within our study, we also observed six patients with a clinically relevant disagreement between
PSMA-TV (Syngo.via) and BR. We had a closer look at the follow-up of these patients. While
PD classification due to a rise in PSMA-TV was not associated with death in the post-therapeutic
follow-up period, a PD status due to BR was associated with three of four patients deceased during
follow-up—indicating that PSMA-TV cannot outperform BR as the current gold standard for therapy
monitoring of CRPC patients. Of course, more research is needed to thoroughly address this question.
Finally, we want to summarize some important limitations of our study. First, treatment and
follow-up were not completely standardized due to the retrospective study design. Second, the
sample size of our study is relatively small, but we focused on a clinically homogenous group
(metastasized CRPC patient receiving taxane-based chemotherapy) rather than on a high sample
size. Third, as segmentation was carried out by two researchers and decisions were made by consensus,
we cannot show data for interrater reliability. Although this was not the primary aim of this study, this
topic surely merits further research efforts. Fourth, we only picked out two software tools from a larger
pool of different platforms. However, we think that choosing a freeware solution for comparison is
an attractive approach—as other researchers could compare this application with their commercial
in-house solutions.
5. Conclusions
Due to the high levels of statistical and clinical agreement in our study cohort of CRPC
patients undergoing taxane-based chemotherapy, comparing PSMA-TV and TL-PSMA determined
by Syngo.via and FIJI appears feasible. Accordingly, comparing PSMA-TV and TL-PSMA between
different departments, e.g., in large multi-centre studies, seems safe.
In our cohort, prognostic potential of PSMA-TV was not superior to BR.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/5/1390/s1,
Table S1: raw data regarding PSMA-TV and TL-PSMA counts for each patient of our study cohort.
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